Markets

Obsidian Therapeutics Enrolls First Participant In Its Phase 1/2 Agni-01 Trial Of Amsokigene Autoleucel To Treat Advanced Or Metastatic Melanoma

Aug 5, 2026 · 07:21 AM ET· updated 2h ago

Obsidian Therapeutics, Inc. ("Obsidian") (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell

Why It Matters

Obsidian started testing a new cancer medicine on real patients for the first time. This is an early step that shows the company is moving forward, but it will take a long time to know if the medicine actually works.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OBX29.00

-5.00 (-14.71%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.